| Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | 1. Organization and Summary of Significant Accounting Policies Organization and Business Senomyx, Inc. (“we”, “us” or “our”) was incorporated in Delaware in September 1998 January 1999. We currently have product discovery, development and commercialization collaborations with some of the world’s leading packaged food, beverage and ingredient companies: Ajinomoto Co., Inc. (“Ajinomoto”), Firmenich SA (“Firmenich”) and PepsiCo, Inc. (“PepsiCo”). Our collaboration agreements generally provide for license fees, research and development funding, reimbursement of certain costs, development milestone payments based upon our achievement of research or development goals and, in the event of commercialization, commercial milestone payments, minimum periodic royalties and royalties on sales of products incorporating our flavor ingredients. We also sell certain flavor ingredients directly to flavor companies for inclusion in flavor systems for re-sale to food and beverage companies. Basis of Presentation The financial statements at June 30, 2018 six June 30, 2018 2017 three six June 30, 2018 not may December 31, 2018. December 31, 2017, 10 December 31, 2017 The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred net losses from operations since inception and have an accumulated deficit of $285.5 June 30, 2018. June 30, 2018 $14.7 12 Use of Estimates The preparation of financial statements in conformity with United States generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We consider all highly liquid investments with a remaining maturity of three Short-Term Investments Available-for-Sale Our surplus cash is generally invested in United States government agency securities and corporate debt securities with maturity dates of two Fair Value of Financial Instruments other than Short-Term Investments Available-for-Sale The carrying amount of cash and cash equivalents, accounts receivables, accounts payable and accrued expenses are considered to be representative of their respective fair value because of the short-term nature of those items. Accounts Receivable We extend credit to our customers in the normal course of business based upon an evaluation of the customer’s credit history, financial condition and other factors. Estimates of allowances for uncollectible receivables are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due and other factors. At June 30, 2018 December 31, 2017, not Inventories Inventories consist entirely of purchased finished goods. Inventories are valued at lower of cost (on a moving average basis) or net realizable value. We are required to make assumptions regarding the level of reserves required to value items at the lower of cost or net realizable value. We make judgments and estimates regarding excess or obsolete inventory by analyzing forecasted demand, pricing trends, margins, product life cycles, remaining shelf life and expectations of efficacy, as well as qualitative factors given the limited sales history of our products. At June 30, 2018 December 31, 2017, $395,000 Revenue Recognition We recognize revenues when we transfer control of promised goods or services to our collaborators and customers in an amount that reflects the consideration to which we expect to be entitled to in exchange for those goods or services. See Note 2 Cost of Commercial Revenues Cost of commercial revenues represents royalties payable under our third Research, Development and Patents Research and development costs, including those incurred in relation to our collaboration agreements, are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, facilities and depreciation, research and development supplies, licenses and outside services. Such research and development costs totaled $3.5 $3.8 three June 30, 2018 2017, $7.0 $7.8 six June 30, 2018 2017. Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. We include all external costs related to the filing of patents related to development in Research, Development and Patents expenses. Such patent-related expenses totaled $0.6 $0.5 three June 30, 2018 2017, $1.0 $0.9 six June 30, 2018 2017. Stock-Based Compensation Total stock-based compensation expenses recognized for the three June 30, 2018 2017 Three Months E nded , Six Months Ended June 30, 201 8 201 7 201 8 201 7 Research, development and patents $ 210 $ 354 $ 482 $ 651 Selling, general and administrative 275 543 537 1,040 Total stock-based compensation expenses $ 485 $ 897 $ 1,019 $ 1,691 At June 30, 2018, $2.5 2.5 Net Loss Per Share Basic earnings per share (“EPS”) is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income or loss by the weighted average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common share equivalents include the dilutive effect of in-the-money shares, which is calculated based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of a share and the amount of compensation cost, if any, for future service that we have not The following table sets forth the computation of basic and diluted net loss per share for the respective periods. Three Months Ended June 30 , Six Months Ended June 30 , 201 8 201 7 201 8 201 7 Numerator: Net loss (in thousands) $ (3,646 ) $ (2,828 ) $ (7,403 ) $ (6,264 ) Denominator: Weighted average common shares 48,311,563 47,514,233 48,139,257 46,682,641 Basic and diluted net loss per share $ (0.08 ) $ (0.06 ) $ (0.15 ) $ (0.13 ) Outstanding antidilutive securities not included in diluted net loss per share calculation: Options to purchase common stock 10,838,761 11,097,049 10,838,761 11,097,049 Comprehensive Income (Loss) The Comprehensive Income Topic of the FASB ASC requires that all components of comprehensive income (loss), including net income (loss), be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our accumulated other comprehensive loss as of June 30, 2018 December 31, 2017 Segment Reporting We operate in one Recent Accounting Pronouncements In February 2016, 2016 02, Leases December 15, 2018, 2016 02 first 2019. |
